Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2010

USC Researcher Gets $2.3M to Build Real-Time Nanolaser DNA Imaging Tool

USC Researcher Gets $2.3M to Build Real-Time Nanolaser DNA Imaging Tool

Device will be designed to assess carcinogens and their induced changes in cells. [USC Viterbi School of Engineering]

  • NIH will award Andrea Armani of the University of Southern California $2.3 million over five years to develop an ultrasensitive nanolaser that would allow her to detect changes in DNA as they're happening in real-time. The first part of the project focuses on building the nanolaser instrument, while the second half will concentrate on DNA experiments.

    Current research methods are only able to capture snapshots of these DNA changes instead of monitoring the process continuously, points out Armani, an assistant professor at the Mork Family department of chemical engineering and materials science. The sensitivity or resolution of many of these techniques is also very poor, she adds.

    Armani’s device will be designed such that as DNA binds to the surface of the nanolaser, the color or lasing wavelength emitted by the laser will change. As the DNA changes, the color will change again.

    The improved resolution is a result of the precision with which the color can be monitored. This device will allow Armani to study a single DNA strand in isolation rather than groups of hundreds to thousands of strands as is currently the norm.

    Armani’s goal is to pinpoint triggers for cancer. She will focus first on using the nanolaser to perform initial proof-of-concept experiments using known triggers such high concentrations of common solvents and cleaning agents. Part of this process involves taking a single strand of DNA, exposing it to a harsh chemical, and seeing whether a specific change is initiated. Ultimately she'd like to be able to warn people which triggers to avoid.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »